

NOTICE OF INTENT

Department of Health and Hospitals Board of Pharmacy

LAC 46:LIII.2901

In accordance with the provisions of the Administrative Procedure Act (La. R.S. 49:950 *et seq.*) and the Louisiana Pharmacy Practice Act (La. R.S. 37:1161 *et seq.*), the Louisiana Board of Pharmacy hereby gives notice of its intent to amend the definition of one term found in §2901 of Chapter 29 – Prescription Monitoring Program. In particular, the proposed rule will identify two drug products in the definition of ‘drugs of concern.’

Interested persons may submit written comments to Malcolm J Broussard, Executive Director, Louisiana Board of Pharmacy, 5615 Corporate Blvd., 8th Floor, Baton Rouge, LA 70808-2537. He is responsible for responding to inquiries regarding this proposed rule. A public hearing on these proposed rules is scheduled for Wednesday, January 27, 2010 at 9:00 a.m. in the Board office. At that time, all interested persons will be afforded an opportunity to submit data, views, or arguments, either orally or in writing. The deadline for the receipt of all comments is 12:00 noon that same day.

Malcolm J Broussard
Executive Director
Louisiana Board of Pharmacy

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

* * *

Chapter 29. Prescription Monitoring Program

Subchapter A. General Operations

§2901. Definitions

* * *

“Drugs of concern’ means drugs other than controlled substances which demonstrate a potential for abuse, including any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, ethers, isomers, and salts of isomers [whenever the existence of such salts, esters, ethers, isomers, and salts of isomers is possible within the specific chemical designation]: (1) butalbital when in combination with at least three hundred twenty five milligrams of acetaminophen per dosage unit, and (2) tramadol.

* * *

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1345 (July 2007), amended LR